Wende Hutton specializes in creating asset and team spinouts from big pharma by licensing shelved drugs with strong clinical data and building seasoned executive teams around them, as she did with Labrys Biologics which licensed a migraine antibody from Pfizer and sold to Teva for up to $825M in milestones. She actively spends time with large pharma companies to understand gaps in their franchises and what assets they want to acquire, then uses that intelligence to shape Canaan's early-stage investing strategy in a market where most newly approved drugs now come from venture-backed biotech companies.

• Champions breakthrough biotechnology and pharmaceutical innovations, particularly those targeting oncology and rare diseases. Highlights specific advancements such as Day One Biopharmaceuticals developing drugs for pediatric brain tumors and Qlaris working on novel treatments for underserved glaucoma patients.
• A focus on digital health platforms that modernize care delivery and improve chronic condition management. Frequently celebrates milestones for portfolio companies like Glooko, which uses data to assist diabetes patients, and Ambra Health, a vendor for medical image exchange.
• Supports mission-driven startups that aim to solve systemic social issues and promote equity. Praised Mobility Capital Finance for its efforts to bridge the gap for the unbanked in cities and often amplifies voices calling for unity and solutions to racial inequality in the business world.
• Values scientific literacy and data-driven public health policy. Has stressed the importance of education that fosters respect for scientific data and community responsibility, particularly when analyzing responses to global health crises.
• Advocates for diverse leadership within the tech and healthcare sectors. Shared articles connecting successful pandemic responses to female leadership and actively welcomes new executives with deep domain expertise to the boards of her portfolio companies.